English
/
中文
We are a growing Chinese pharmaceutical company developing therapeutics for patients in China and beyond.
Our first program is the IL-17A mAb licensed from Janssen.
Our team brings together scientists from China, the US and Europe who have expertise in drug discovery and development.
Our current focus is therapeutics for auto-immune disease and cancer.
WHO WE ARE
HOME
Home
WHO WE ARE
Nav
WHAT WE DO
Nav
INVESTORS
Nav
PIPELINE
Nav
NEWS
Nav
CAREERS
Nav
CONTACT US
Nav
HISTORY
LEADERSHIP
ADVISORS
BOARD OF DIRECTORS
LEADERSHIP
Yanliang Ch
u
CEO
Ruiqi
Meng
Deputy General Manager
Hui Song
Deputy General Manager
Secretary of the Board
Kuiqi
Wang
Better affordable medicines for patients in China and beyond.
Contact US ▶